179 related articles for article (PubMed ID: 23752663)
1. Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison.
Gellad WF; Donohue JM; Zhao X; Mor MK; Thorpe CT; Smith J; Good CB; Fine MJ; Morden NE
Ann Intern Med; 2013 Jul; 159(2):105-14. PubMed ID: 23752663
[TBL] [Abstract][Full Text] [Related]
2. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
3. Impact of formulary restrictions on medication use and costs.
Shen X; Stuart BC; Powers CA; Tom SE; Magder LS; Perfetto EM
Am J Manag Care; 2017 Aug; 23(8):e265-e274. PubMed ID: 29087150
[TBL] [Abstract][Full Text] [Related]
4. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
Sacks CA; Lee CC; Kesselheim AS; Avorn J
JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
[TBL] [Abstract][Full Text] [Related]
5. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
7. Sources of regional variation in Medicare Part D drug spending.
Donohue JM; Morden NE; Gellad WF; Bynum JP; Zhou W; Hanlon JT; Skinner J
N Engl J Med; 2012 Feb; 366(6):530-8. PubMed ID: 22316446
[TBL] [Abstract][Full Text] [Related]
8. Variation in prescription use and spending for lipid-lowering and diabetes medications in the Veterans Affairs Healthcare System.
Gellad WF; Good CB; Lowe JC; Donohue JM
Am J Manag Care; 2010 Oct; 16(10):741-50. PubMed ID: 20964470
[TBL] [Abstract][Full Text] [Related]
9. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
[TBL] [Abstract][Full Text] [Related]
10. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
Hoadley JF; Merrell K; Hargrave E; Summer L
Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
[TBL] [Abstract][Full Text] [Related]
11. The association of Medicare drug coverage with use of evidence-based medications in the Veterans Health Administration.
Johnson ML; Petersen LA; Sundaravaradan R; Byrne MM; Hasche JC; Osemene NI; Wei II; Morgan RO
Ann Pharmacother; 2009 Oct; 43(10):1565-75. PubMed ID: 19706740
[TBL] [Abstract][Full Text] [Related]
12. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available.
Dusetzina SB; Cubanski J; Nshuti L; True S; Hoadley J; Roberts D; Neuman T
Health Aff (Millwood); 2020 Aug; 39(8):1326-1333. PubMed ID: 32744944
[TBL] [Abstract][Full Text] [Related]
13. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
14. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
[TBL] [Abstract][Full Text] [Related]
15. Dual Receipt of Prescription Opioids From the Department of Veterans Affairs and Medicare Part D and Prescription Opioid Overdose Death Among Veterans: A Nested Case-Control Study.
Moyo P; Zhao X; Thorpe CT; Thorpe JM; Sileanu FE; Cashy JP; Hale JA; Mor MK; Radomski TR; Donohue JM; Hausmann LRM; Hanlon JT; Good CB; Fine MJ; Gellad WF
Ann Intern Med; 2019 Apr; 170(7):433-442. PubMed ID: 30856660
[TBL] [Abstract][Full Text] [Related]
16. Impact of medicare part D plan features on use of generic drugs.
Tang Y; Gellad WF; Men A; Donohue JM
Med Care; 2014 Jun; 52(6):541-8. PubMed ID: 24824538
[TBL] [Abstract][Full Text] [Related]
17. Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary.
Feldman WB; Rome BN; Lehmann LS; Kesselheim AS
JAMA Intern Med; 2020 Apr; 180(4):597-601. PubMed ID: 32011624
[TBL] [Abstract][Full Text] [Related]
18. Part D's underuse of generics wastes $1B per year.
Manag Care; 2013 Jul; 22(7):68. PubMed ID: 23940871
[No Abstract] [Full Text] [Related]
19. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
DeJong C; Aguilar T; Tseng CW; Lin GA; Boscardin WJ; Dudley RA
JAMA Intern Med; 2016 Aug; 176(8):1114-1122. PubMed ID: 27322350
[TBL] [Abstract][Full Text] [Related]
20. Medicare Part D: Patients Bear The Cost Of 'Me Too' Brand-Name Drugs.
Gastala NM; Wingrove P; Gaglioti A; Petterson S; Bazemore A
Health Aff (Millwood); 2016 Jul; 35(7):1237-40. PubMed ID: 27385239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
